ArgoBio is a biotech startup that specializes in the creation of therapeutics-based companies. Their business model is centered around using innovative scientific breakthroughs to develop new companies that focus on translational research projects. These projects are typically in the early stages and are supported by ArgoBio's €50 million funding, which is used to launch and nurture these projects until they reach the Series A financing stage.

ArgoBio operates in the biotech market across Europe and beyond, with teams based in France and the UK. Their clients are primarily early-stage research projects and academic research teams that are developing therapeutic solutions. ArgoBio provides these teams with operational support, offering the expertise of seasoned scientists and entrepreneurs to help mature their projects.

The company's revenue is likely generated through the successful incubation and subsequent financing of these new biotech companies. This process includes translational work at the academic lab by the principal investigator and at Contract Research Organizations (CROs) for preclinical testing, toxicity testing, and manufacturing.

ArgoBio is backed by five complementary investors and has built a diverse pipeline of projects, indicating a broad interest in various therapeutic indications and modalities. The team at ArgoBio is experienced and has a proven track record in both science and entrepreneurship, which positions them well for success in the competitive biotech industry.

Keywords: Biotech, Therapeutics, Translational Research, Early-stage Projects, Series A Financing, Operational Support, Incubation, Preclinical Testing, Entrepreneurship, Pipeline of Projects.